Belbuca was Collegium Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $221.65M of $780.57M (28%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Xtampza Er | $138.80M | $177.37M | $191.33M | $199.31M | |||||
| Belbuca | $126.46M | $182.10M | $211.27M | $221.65M | |||||
| Nucynta Ir | $112.06M | $108.15M | $100.74M | $115.31M | |||||
| Jornay Pm | — | — | $37.24M | $148.86M | |||||
| Nucynta Er | $72.42M | $82.65M | $75.77M | $80.99M | |||||
| Symproic & Other | — | $16.50M | $15.10M | $14.45M | |||||
| Symproic | $12.27M | — | — | — | |||||
| Other | $1.93M | — | — | — | |||||
| Total | $463.93M | $566.77M | $631.45M | $780.57M |
Collegium Pharmaceutical brought in $780.57M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 23.6% from $631.45M in fiscal 2024. Belbuca was the largest at $221.65M (28.4%), ahead of Xtampza Er at $199.31M (25.5%) and Jornay Pm at $148.86M (19.1%). The other three lines brought in $210.75M combined.
Compared with fiscal 2024, Jornay Pm grew fastest, up 299.7% to $148.86M. Every line above 2% of revenue grew.
Collegium Pharmaceutical began breaking out Jornay Pm in fiscal 2024 and Symproic & Other in fiscal 2023. Collegium Pharmaceutical stopped reporting Symproic ($12.27M in fiscal 2022) and Other ($1.93M in fiscal 2022) as separate lines.
Collegium Pharmaceutical (COLL) reports its revenue by product and service. In fiscal 2025, Belbuca was its largest product and service line, bringing in $221.65M (28.4% of the total), followed by Xtampza Er at $199.31M (25.5%).
Belbuca was Collegium Pharmaceutical's largest product and service line in fiscal 2025, bringing in $221.65M, or 28.4% of the $780.57M total across its six product and service lines.
Among Collegium Pharmaceutical's product and service lines that make up at least 2% of revenue, Jornay Pm grew fastest in fiscal 2025, up 299.7% from $37.24M to $148.86M.
Every figure comes from Collegium Pharmaceutical's annual financial filings, as reported. Each line keeps the name Collegium Pharmaceutical gives it, and years follow its fiscal calendar.
Collegium Pharmaceutical's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.